AIP
SGMT icon

Ameritas Investment Partners’s Sagimet Biosciences SGMT Stock Holding History

Ameritas Investment Partners’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-525
Closed -$2.85K – 3221
2024
Q1 		$2.85K Hold
525
– – ﹤0.01% 3007
2023
Q4 		$2.85K Hold
525
– – ﹤0.01% 3041
2023
Q3 		$4.62K Buy
+525
New +$6.99K ﹤0.01% 3005

Other funds holding SGMT

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Ameritas Investment Partners's SGMT Position: Q2 2024 in Review

Ameritas Investment Partners sold out of Sagimet Biosciences (SGMT) in Q2 2024, closing a stake of 525 shares — an estimated $2.85K sold.

Ameritas Investment Partners first reported a position in SGMT in Q3 2023 and held it in 3 quarters. The position peaked at $4.62K in Q3 2023. 82 funds tracked by Wall St. Rank hold SGMT as of Q2 2024.

  • Ameritas Investment Partners reported no remaining Sagimet Biosciences position as of Q2 2024 after selling out during the quarter.
  • Ameritas Investment Partners sold 525 Sagimet Biosciences shares in Q2 2024, an estimated $2.85K.
  • Ameritas Investment Partners first reported a position in Sagimet Biosciences in Q3 2023 and held it in 3 quarters.
  • Ameritas Investment Partners's Sagimet Biosciences position peaked at $4.62K in Q3 2023.
  • 82 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2024.

Based on Ameritas Investment Partners's 13F filing for Q2 2024, filed 13 Aug 2024.